this process is catalyzed by the enzyme methionine adenosyltransferases
Its most well-known iteration, CJC-1295 DAC, was developed by the Canadian biotech company ConjuChem Technologies in the mid-2000s [1]
Symptoms of Deficiency Fatigue and weakness
A review on BPC-157 and gastric cytoprotection describes it as a stable gastric pentadecapeptide with anti-ulcer and tissue-protective effects and notes that it has been used in trials for ulcerative colitis
Simultaneous activation of tissue repair, anti-inflammatory, immune, and regenerative pathways addresses healing from every angle for optimal outcomes
Others experience it as a loss of pleasure or mild emotional flatness around food. Trial mood scores moved slightly better rather than worse, so the negative experience appears to be a minority signal that standard adverse-event tables do not capture well